Patent Law Updates | New Statutes, Regulations and Rules

December 30, 2011

USPTO Extends Deadline to Participate in Green Technology Pilot Program

Sunset of the Patent Application Backlog Reduction Stimulus Plan and a Limited Extension of the Green Technology Pilot Program
USPTO No. 11-72, Docket No. PTO–P–2011–0078, 12/15/2011

USPTO Extends Deadline to Participate in Green Technology Pilot Program

The United States Patent and Trademark Office (USPTO) has announced that the deadline for filing petitions under the Green Technology Pilot Program, originally set to expire on December 31 of this year, is being extended through March 30, 2012 or until 3,500 applications have been accorded special status under the program.

Additionally, USPTO also announced that the Patent Application Backlog Reduction Stimulus Plan (Project Exchange) will not be extended through its current expiration date of December 31, 2011.

“In view of the success of the Green Technology Pilot Program the program will be extended until we receive 3,500 applications or reach the final program sunset date,” said Under Secretary of Commerce for Intellectual Property and Director of the USPTO David Kappos. “While both the Green Technology and Project Exchange programs will soon draw to a close, in the future all applicants may use the newly enacted Prioritized Examination (Track I) program, which is currently available to all technologies and categories of invention, to have their application accorded special status.”

Program statistics show that stakeholders participating in the Green Technology Pilot Program have obtained patents much more quickly as compared to the standard examination process.  Currently, the average time between granting of a green technology petition and first office action on the merits is just 78 days.

In many instances, applicants have had their Green Technology inventions patented in less than one year from the application filing date. More than 2,900 petitions have been granted to green technology patent applicants since the pilot began in December 2009.

Prioritized Examination Track (Track I), which is part of the USPTO’s Three-Track Program, provides applicants with greater control over when their applications are examined and promotes greater efficiency in the patent examination process. Track I allows applicants, for a fee, to have their patent applications processed to final disposition within 12 months from prioritized status being granted.

View a PDF of the rule

Also See:

USPTO to Implement Inventor’s Oath or Declaration Provisions of the Leahy-Smith America Invents Act

U.S. Patent and Trademark Office Seeks Public Input on Proposed Fees

USPTO to Test New Post Final Rejection Option

USPTO Expands Patent Law School Clinic Certification Pilot Program

USPTO Launches Small Business Innovation Research Pilot Program

Companies Mentioned

Patent Law

The following companies are mentioned in Patent Law Updates:

Boston Scientific Corp.

Microsoft Corp.

Samsung Electronics America, Inc.

Cordis Corp.

Boston Scientific Scimed, Inc.

U.S. Patent and Trademark Office

Stryker Corp.

Acumed, LLC

Quanta Computer, Inc.

Sanyo North America Corp.

LG Electronics, Inc.

Smith & Nephew, Inc.

Cohesive Technologies, Inc.

Waters Corp.

Swisa, Inc.

Egyptian Goddess, Inc.

Motorola, Inc.

Dror Swisa

Johnson & Johnson, Inc.

Target Corp.

Sears Holding Corp.

Prometheus Laboratories, Inc.

Mayo Collaborative Services d.b.a. Mayo Medical Laboratories

Kohl’s Department Stores, Inc.

K-Mart Corp.

J.C. Penney Company, Inc.

Audiovox Communications Corp.

Glamourmom LLC

McKesson Information Solutions, Inc.

Federated Department Stores

Bridge Medical, Inc.

Elizabeth Lange LLC d.b.a. Liz Lange Maternity

United States Patent and Trademark Office

Smithkline Beecham Corp. (d.b.a. GlaxoSmithKline, plc.)

SmithKline Beecham PLC

HT Window Fashion Corp.

SmithKline Beecham Corp. d.b.a GlaxoSmithKline

Scimed Life Systems Inc.

Ortho-McNeil Pharmaceutical, Inc.

Glaxo Group Limited d.b.a. GlaxoSmithKline

Mylan Pharmaceutical, Inc.

Ranbaxy, Inc.

Mylan Laboratories, Inc.

Nokia, Inc.

Teva Pharmaceuticals USA, Inc.

Stryker Sales Corp.

Stryker Orthopaedics

Howmedica Osteonics Corp.

Teva Pharmaceuticals Industries, Ltd.

Abbot Laboratories

Additional Resources

Patent Law

Further Reading in Patent Law

Other Recent Summaries

Recent Expert Legal Commentaries